| "Rush" regimen for anaphylaxis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| "Rush" regimen for egg hypersensitivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| "Rush" regimen for milk hypersensitivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abatacept for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| allogeneic hematopoietic stem cell transplantation + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Alpha-galactosylceramide for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AR101 for peanut hypersensitivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AR101 powder provided in capsules & sachets for peanut hypersensitivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for graft vs host disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR for x-linked combined immunodeficiency diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Belimumab+SOC for antiphospholipid syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bezuclastinib for immune complex diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for autoimmune diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Corticosteroids + Ruxolitinib for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| cow's milk for food hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide for graft vs host disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
|---|
| Dapagliflozin for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| DBFC with 150g of Alpha-gal Knock Out (KO) pork + DBFC with 150g of Wild Type (WT) pork for food hypersensitivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Decidual Stromal Cells for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Direct intravenous injection of ivlv-X1 lentiviral vector for x-linked combined immunodeficiency diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Efgartigimod alfa for immunoglobulin g4-related disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Fecal microbiota for peanut hypersensitivity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| fetal MSCs combined with 4SCAR T cells for autoimmune diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FMXIN002 double dose + FMXIN002 double dose + NAC + FMXIN002 single dose + FMXIN002 single dose + NAC + Epinephrine for anaphylaxis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Food allergy desensitization / Oral Immunotherapy for egg hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Food allergy desensitization / Oral Immunotherapy for milk hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Food allergy desensitization / Oral Immunotherapy for peanut hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GVHD prophylaxis regimen + RIC regimen for immune system diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Haploidentical Hematopoietic Cell Transplantation for primary immunodeficiency diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + FLUDARABINE + Tacrolimus for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Tacrolimus for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High dose of peanuts for peanut hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High dose OIT for peanut hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| INP20 for peanut hypersensitivity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Multi-Allergen Oral Immunotherapy + Omalizumab for peanut hypersensitivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nut oral desensitization for nut hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Omalizumab for anaphylaxis | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Omalizumab for food hypersensitivity | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Omalizumab for peanut hypersensitivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Oral immunotheraphy (OIT) for nut hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Oral immunotheraphy (OIT) for peanut hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Oral immunotherapy with peanut for peanut hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paxlovid 10 days for immunologic deficiency syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Paxlovid 10 days + REMDESIVIR for immunologic deficiency syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paxlovid 5 days for immunologic deficiency syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Paxlovid 5 days + REMDESIVIR for immunologic deficiency syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peanut for anaphylaxis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peanut for peanut hypersensitivity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| Peanut in common foods or supermarket-sourced cow's milk (CM) for peanut hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peanut oral immunotherapy for anaphylaxis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peanut oral immunotherapy for peanut hypersensitivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| peanut powder for food hypersensitivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for graft vs host disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for immunologic deficiency syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Established Dose from prior study, NCT03810196 for immunologic deficiency syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for immunologic deficiency syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo for Multi-Allergen Oral Immunotherapy + Omalizumab for peanut hypersensitivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Probiotic for hypersensitivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Purified peanut protein extract for peanut hypersensitivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| Purified peanut protein extract + peanut for peanut hypersensitivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| reduced-dose PTCy for graft vs host disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Remestemcel-l for graft vs host disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rivogenlecleucel + rimiducid for primary immunodeficiency diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rovadicitinib for graft vs host disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxolitinib for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for graft vs host disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Total Body Irradiation 12 Gy + Total Body Irradiation 8 Gy for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| αβ T-cells depletion + Cyclophosphamide for graft vs host disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|